The commodity trade you can't miss

This chart is forming a 50-year base! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

Sunday, December 15, 2024 It's day three of the ASC Research Team covering for me while I'm away.    You've already heard from Sam and Louis. Today, you're meeting one of our newest team members with a great trade idea for you…    Show him some love.   JC Can't Miss This Trade   Hi, I'm Jason, one of the newest traders to join the All Star Charts team, and I'm pumped to be here.   Who in their right mind hires a guy who used to get paid to do backflips for a living? Oh, right… JC would. Because, let's face it, everyone needs a gunslinging CTA (Futures Trader) in their life.   My story? Not exactly what you'd call "traditional." I started as a professional athlete and my great great uncle taught me more about trading and economics than he probably realized. But life doesn't always play fair. I took some hits, like rupturing my spleen, battling a bone infection, and going through not one, not two, but FIVE knee surgeries. Yeah, fun times.   But you know what? Those curveballs became my fuel. They pushed me to take the grit and discipline I learned in sports and apply it to business and investing.   By 2015, I was managing money for clients. By 2018, I wasn't just playing the game, I was beating the $SPX every year. These days, I'm all about macro markets: commodities, currencies, country indices, sectors, crypto, bonds… if it moves, I'll trade it.   My style? I'm an outlier hunter. Outliers are those rare, game-changing market moves that break all the rules and make all the difference. Hidden in the noise, they're the trades that deliver the kind of returns most people only dream about.   Recent hits? Bitcoin: 141% YTD, 396% since we got in. Cocoa was another great example this year.     So, the big question is: What outliers are out there today?   Let's hunt. 👊   Backtests, scans, you name it. It's all about finding the next big trade.   That brings me to Silver. This time of year offers an incredible seasonal setup for precious metals. The green bars on the chart represent the positive years and the magnitude of silver's moves during each year. In the lower pane, you'll find the detrended model, which highlights the movement we're preparing to trade.   The backtest is over the past 30 years!     Right now, silver is giving us a massive opportunity.   For short-term traders, holding silver from December 16 through February 14 has an 80% win rate. That's huge. Plus, the median drawdown is just -5.77% (pretty chill for silver).    Tight stop, easy trade, big potential.    Throw in some call options, and suddenly that 10% average gain turns into 100-200%.   But wait, there's more. Did you know silver's building a 50-year base? Yep, this isn't just some shiny metal, it's primed for something massive.     At The Gold Rush, we've been navigating this all year. Sam Gatlin and I have made some insane trades for our members. If you're a precious metals bull, it's been a golden time.   Right now, silver's targeting $50 over the next 6-12 months and our entry this year was at $23.62. Once we clear $50, our next target is $100!   Stay tuned, folks. We're just getting started.   Follow along with my full commodities analysis in All Star Charts Gold Rush. Join here and I'll see you inside! Are you Joining Us In New York? The next Portfolio Accelerator event is happening next month in New York. I'll be there, along with JC and the rest of the analyst team.    This is an amazing chance to attend two full days of market discussion in an intimate setting with like-minded traders and investors.   Apply to join us in New York here.   Jason Perz | ASC Gold Rush All Star Charts emails are a financial publication of general circulation and only offers impersonal advice, not tailored to individual needs of a specific client or group. Any comments or statements made herein do not necessarily reflect those of All Star Charts or its affiliates (collectively, "All Star Charts") and do not constitute buy or sell recommendations. Unless specifically indicated, this message is not an official confirmation of any transaction. The contents of any email communications to or from All Star Charts may be monitored or reviewed at All Star Charts's discretion. All Star Charts accepts no responsibility for any loss or damage arising in any way from the use of this transmission and any attachments; it is the responsibility of the recipient to ensure that they are virus free. If you reply to this email, please note that we are a public investor and do not want any material non-public information. We do not agree to keep confidential any information you provide and do not agree to any restrictions on our trading activity, except pursuant to a written confidentiality agreement executed by All Star Charts. Want to change how you receive these emails? You can manage your preferences here unsubscribe . © 2024 All Star Charts

The Goalposts Are in Another Dimension

Fartcoin is worth more than 20% of all public companies, lol. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

Saturday, December 14, 2024 Our series of guest posts written by members of the All Star Charts research team continues...    Today's note is from our Senior Crypto Analyst. If you're not following what's been going on in crypto, you're missing out...   JC   The Goalposts Are in Another Dimension Kia ora!   I'm Louis Sykes, the Senior Crypto Analyst here at All Star Charts.    When JC casually dropped that he was escaping to Disney World for an entire week, I thought he was pulling my leg.   An entire week?   At Disney World?   As a humble Kiwi where our idea of a theme park is basically a few rides and a half-day commitment, this sounded like some parallel universe of leisure. "It's not just a park," he explained, his voice brimming with childlike excitement. "The hotel's basically a playground, and there are multiple theme parks surrounding you." Multiple? In New Zealand, we consider a carousel and a mediocre rollercoaster a full day's entertainment. This was like hearing about a theme park multiverse. Speaking of multiverses that boggle the mind, Bitcoin just hit $100,000. This has been our first target of this bull market for years. Above there, $155,000 could be next. Much like JC's Disney adventure seems almost surreal to my humble sensibilities, this milestone represents a journey far beyond what many thought possible. Now we're in the fascinating zone of watching how this will resolve; will it rip right through or will it pause here?   We're already seeing the market respect this level with Bitcoin trading sideways these last few weeks.   Ethereum and Solana are also testing important areas of overhead supply. I'm watching $4,100 and $260, respectively.   But despite this resistance levels coming into play, I'm still seeing some healthy (or should I say hilarious) rotations down the cap scale.   Fartcoin just hit a market cap of $750M, which is greater than 20% of all public companies in the Russell 3000. Some days, this market doesn't just move the goalposts of what's normal - it teleports them to another dimension. Need More Crypto In Your Life? Every morning, I'll tell you exactly what's happening in crypto—what's pumping, what's tanking, and why Fartcoin is somehow worth more than 600 public companies. No jargon. No fluff. Just the stuff you actually care about, written by someone who lives and breathes this market (and still chuckles at Fartcoin). Sign up here—it's RISK FREE, takes 10 seconds, and if you hate it, you can unsubscribe faster than a meme coin rug-pull.   See you in there!   - Louis   Come Meet Us In New York Our highest level members and analysts are meeting up in person and we want you to join!   Network with other traders, learn from the experts, and build relationships in the industry.    We're here for it, are you? Apply to join us here.    Louis Sykes | Senior Crypto Analyst, All Star Charts All Star Charts emails are a financial publication of general circulation and only offers impersonal advice, not tailored to individual needs of a specific client or group. Any comments or statements made herein do not necessarily reflect those of All Star Charts or its affiliates (collectively, "All Star Charts") and do not constitute buy or sell recommendations. Unless specifically indicated, this message is not an official confirmation of any transaction. The contents of any email communications to or from All Star Charts may be monitored or reviewed at All Star Charts's discretion. All Star Charts accepts no responsibility for any loss or damage arising in any way from the use of this transmission and any attachments; it is the responsibility of the recipient to ensure that they are virus free. If you reply to this email, please note that we are a public investor and do not want any material non-public information. We do not agree to keep confidential any information you provide and do not agree to any restrictions on our trading activity, except pursuant to a written confidentiality agreement executed by All Star Charts. Want to change how you receive these emails? You can manage your preferences here unsubscribe . © 2024 All Star Charts

Finding My Edge

And why my favorite industry group is biotech. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

Friday, December 13, 2024 [Editors Note] Getting away from the screens is healthy for the soul.   It's important in order to keep the mind right.   And perhaps, I should add, that it's great for the bottom line.   Trust me.   I've been there.   Get away for a few days. Your portfolio returns will thank you.    And I'm eating my own cooking here. I'm leaving for a few days, so you'll be hearing from different members of the ASC Research Team while I'm away.   Some of them you already know well. Some you're just getting to know. And others you're meeting for the fist time.   So try to be nice!   And please don't let them burn the place down while I'm gone.   I'll be back next week!   JC Finding My Edge In Biotech My family has always been a healthcare family - I'm the son of a nurse and a pharmacist. When I was 15, they turned their passion for healthcare into an entrepreneurial venture, starting our community's only locally-owned pharmacy.  I spent many weekends helping out with whatever needed to be done, and gained knowledge of the pharmaceutical industry while other kids were playing Fortnite. Seeing the intersection between science and retail was fascinating, from the lab to the pharmacy shelf.  I witnessed first-hand the approval and widespread adoption of Novo Nordisk's Ozempic and how much it costs to order a refrigerator full of it (it's a lot!). I was born in 2002, so while I was being conceived, the NYSE Biotechnology Index bottomed and entered a 2,000% secular uptrend. What's more, Humira, the biggest blockbuster drug of all time, was launched days after I was born. I'm fortunate to have been born at the time I was! Biotechnology at an index level has been dead money for a decade, but I think that's about to change:     JC has been pounding the table on sector rotation into Consumer Discretionary and Technology, but I think he's not paying enough attention to biotechnology.  This industry made investors fortunes earlier this century, but most investors suffer from recency bias and want nothing to do with them.   Before the legendary visionary Steve Jobs passed away over a decade ago, he said, "I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning." Who am I to argue with Steve Jobs? I'm here to profit from companies on innovation's bleeding edge.  Every day, I'm monitoring this list of up & coming biotech stocks:   My universe contains biotech stocks between $1-$10B in market capitalization or about 20% of all investable biotech stocks. That's the sweet spot for me.  I'll leave the speculating on phase 3 readouts to the science nerds. I'm no scientist. I'm looking for companies that recently won FDA approval and are in the early stages of marketing to the masses. This is often accompanied by primary trend reversals and base breakouts, which allow me to define my risk without capping my upside. You can join the waiting list for my new weekly column, Bio-technical Analysis, focused on identifying the biotech industry's most asymmetric risk vs. reward setups. Also, we recently published a free report highlighting the best stocks in the Baker Bros. portfolio. This hedge fund is on another level when it comes to identifying companies in the biotech industry with science that makes money for shareholders.  Thanks for reading!   Sam Gatlin, Analyst, All Star Charts   The Morning Show Is About To Start It's the best morning show in finance, and it's about to go live.    Join Strazza, Spencer, Alfonso, Louis, and Kenny as they discuss all the biggest charts and headlines for today.    Click here to watch. J.C. Parets | Founder, All Star Charts All Star Charts emails are a financial publication of general circulation and only offers impersonal advice, not tailored to individual needs of a specific client or group. Any comments or statements made herein do not necessarily reflect those of All Star Charts or its affiliates (collectively, "All Star Charts") and do not constitute buy or sell recommendations. Unless specifically indicated, this message is not an official confirmation of any transaction. The contents of any email communications to or from All Star Charts may be monitored or reviewed at All Star Charts's discretion. All Star Charts accepts no responsibility for any loss or damage arising in any way from the use of this transmission and any attachments; it is the responsibility of the recipient to ensure that they are virus free. If you reply to this email, please note that we are a public investor and do not want any material non-public information. We do not agree to keep confidential any information you provide and do not agree to any restrictions on our trading activity, except pursuant to a written confidentiality agreement executed by All Star Charts. Want to change how you receive these emails? You can manage your preferences here unsubscribe . © 2024 All Star Charts